Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients

doi:10.3748/wjg.v28.i45.6380

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 45

This Article

(214)

(221)

(0)

(11)

(5352)

(6)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Observational Study

World J Gastroenterol. Dec 7, 2022; 28(45): 6380-6396
Published online Dec 7, 2022. doi: 10.3748/wjg.v28.i45.6380

Table 3 Treatment characteristics of genotype 1b-infected patients treated with direct-acting antiviral

Parameter	GT1b patients, n = 11385
History of previous therapy
Treatment-naïve	8497 (74.6)
Non-responder	949 (8.3)
Relapser	831 (7.3)
Discontinuation due to safety reason	338 (3)
Unknown type of response	728 (6.4)
No data	42 (0.4)
Previous treatment regimen in treatment-experienced, n = 2846
IFN ± RBV	149 (5.2)
PegIFN ± RBV	2080 (73.1)
IFN + RBV + DAA	438 (15.4)
DAA	155 (5.4)
No data	24 (0.9)
Genotype-specific treatment regimens
ASV + DCV	135 (1.2)
LDV/SOF ± RBV	2652 (23.3)
OBV/PTV/r + DSV ± RBV	3685 (32.4)
GZR/EBR ± RBV	2270 (19.9)
Other (SOF ± SMV ± DCV ± RBV, SMV ± DCV ± RBV)	16 (0.1)
Pangenotypic regimens
GLE/PIB	1684 (14.8)
GLE/PIB + SOF + RBV	3 (< 0.1)
SOF/VEL ± RBV	931 (8.2)
VOX/VEL/SOF	9 (0.1)

ASV: Asunaprevir; DAA: Direct-acting antiviral; DCV: Daclatasvir; DSV: Dasabuvir; EBR: Elbasvir; GLE: Glecaprevir; GT: Genotype; GZR: Grazoprevir; IFN: Interferon; LDV: Ledipasvir; OBV: Ombitasvir; PegIFN: Pegylated interferon; PIB: Pibrentasvir; PTV/r: Paritaprevir; RBV: Ribavirin; SMV: Simeprevir; SOF: Sofosbuvir; VEL: Velpatasvir; VOX: Voxilaprevir.

Full Size Table

Citation: Zarębska-Michaluk D, Brzdęk M, Jaroszewicz J, Tudrujek-Zdunek M, Lorenc B, Klapaczyński J, Mazur W, Kazek A, Sitko M, Berak H, Janocha-Litwin J, Dybowska D, Supronowicz Ł, Krygier R, Citko J, Piekarska A, Flisiak R. Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients. World J Gastroenterol 2022; 28(45): 6380-6396
URL: https://www.wjgnet.com/1007-9327/full/v28/i45/6380.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i45.6380

Zarębska-Michaluk D, Brzdęk M, Jaroszewicz J, Tudrujek-Zdunek M, Lorenc B, Klapaczyński J, Mazur W, Kazek A, Sitko M, Berak H, Janocha-Litwin J, Dybowska D, Supronowicz Ł, Krygier R, Citko J, Piekarska A, Flisiak R. Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients. World J Gastroenterol 2022; 28(45): 6380-6396 [PMID: 36533109 DOI: 10.3748/wjg.v28.i45.6380]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.